



Neonatal Morbidities Associated with Histologic Chorioamnionitis Defined Based on the Site and Extent of Inflammation in Very Low Birth Weight Infants

Su Yeong Kim,¹ Chang Won Choi,^{2,3}
Euseok Jung,⁴ Juyoung Lee,^{2,3} Jin A Lee,³
Haeryoung Kim,⁵ Ee-Kyung Kim,³
Han-Suk Kim,³ Beyong Il Kim,^{2,3}
and Jung-Hwan Choi³

¹Department of Pediatrics, Hallym University Kangdong Sacred Heart Hospital, Seoul;

²Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam; ³Department of Pediatrics, Seoul National University College of Medicine, Seoul; ⁴Department of Pediatrics, Asan Medical Center Children's Hospital, Seoul;

⁵Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea

Received: 14 April 2015

Accepted: 1 July 2015

Address for Correspondence:

Chang Won Choi, MD

Division of Neonatology, Department of Pediatrics, Seoul National University Bundang Hospital, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam 13620, Korea
Tel: +82.31-787-7286, Fax: +82.31-787-4054
E-mail: choicw@snu.ac.kr

Funding: This work was supported by the Basic Research Program through the National Research Foundation of Korea funded by the Ministry of Education (2010-0021644).

INTRODUCTION

Histologic chorioamnionitis (HC) is characterized by a maternal inflammatory response that involves neutrophil infiltration in the fetal membranes and/or placenta with or without a fetal inflammatory response (FIR), which is indicated by funisitis (1). HC is a reliable marker for ascending genital tract infection and is a major risk factor for preterm birth and prematurity-associated morbidities (2-8). There have been not a few studies supporting the adverse effects of HC on neonatal outcomes, but controversies continue on this issue.

A recent systematic review of 59 studies reported that the definition of chorioamnionitis varied across the studies (9). Different studies used different definitions; therefore, the true effects of HC have been confounded by the absence of a uniform definition and standardized histologic diagnostic criteria. The current definition of HC encompasses amnionitis, choriodecidualitis, funisitis, and placental inflammation (10). The fetal and neona-

tal impact of HC may be different by the site of inflammation within the uterus. The FIR associated with HC has been known to contribute to adverse neonatal outcomes (11). Yoon et al. (1) reported that funisitis is associated with amniotic fluid infections, neonatal sepsis, and FIR syndrome. Amnionitis is the final stage of extra-placental chorioamniotic inflammation. Park et al. (12) demonstrated that the involvement of amnion in the inflammatory process is associated with a more intense fetal and intra-amniotic inflammatory responses compared with chorioamnionitis alone. In this regard, we focused on funisitis and amnionitis in defining HC. Moreover, not only the site of inflammation but also the extent of inflammation at each site maybe related with fetal and neonatal consequences of HC. Therefore we sub-defined high grade inflammation in each site of HC. The aim of this study was to determine the relationship between HC and neonatal morbidities in very low birth weight (VLBW) infants using the definition of HC that reflects both the site and extent of inflammation.

Keywords: Chorioamnionitis; Amnionitis; Morbidity; Infant, Very Low Birth Weight; Infant, Premature

MATERIALS AND METHODS

Subjects

This study included all VLBW infants with a birth weight of < 1,500 g who were born and admitted at the neonatal intensive care unit at Seoul National University Bundang Hospital between January 2008 and December 2012. We excluded infants with major congenital anomalies and infants whose placentas were not available for pathologic assessment.

Definitions of histologic chorioamnionitis

Placentas are routinely sent for histologic examination immediately after preterm delivery at our center. HC was diagnosed by the presence of acute inflammation and infiltration of polymorphonuclear leukocytes (PMN) in the amnion, chorionic decidua, umbilical cord, or the chorionic plate; and was divided into four grades depending on the extent of PMN infiltration using the grading system devised by Salafia et al. (13) by a single pathologist (Table 1). Based on the histological findings described according to this grading system, we defined HC into four categories based on the site and extent of PMN infiltration: PMN infiltration of any grade in any part of the amnion, chorionic decidua, umbilical cord, and chorionic plate was defined as any HC; PMN infiltration of any grade in the amnion as amnionitis; PMN infiltration of any grade in the umbilical cord as funisitis;

and PMN infiltration of any grade in both the amnion and umbilical cord as amnionitis plus funisitis. Furthermore, the extent of PMN infiltration of grade 3 or higher at each site of inflammation was sub-defined as high grade (HG) (Table 1). We compared the incidences of neonatal morbidities between the VLBW infants with or without HC using the above definitions of HC.

Definitions of clinical terms

Antenatal, perinatal, and neonatal data were retrospectively collected from the original medical records of the infants included in this study. The retrieved data included maternal age, type of delivery, antenatal steroid use, premature rupture of membranes (PROM) > 18 hr, antenatal antibiotic use, the clinical and histologic diagnosis of chorioamnionitis, maternal pre-eclampsia, gestational age (GA), birth weight, gender, multiple births, small for gestational age (SGA), and Apgar scores at 1 and 5 min. Clinical chorioamnionitis was diagnosed by the presence of a fever of 38.3°C or higher, and the presence of at least two of the following: leukocytosis (> 18,000/ μ L), vaginal discharge with foul odor, uterine sensitivity, and tachycardia (maternal > 100/min, fetal > 180/min). SGA was defined as a birth weight below the 10th percentile for GA. Neonatal morbidities included respiratory distress syndrome (RDS), defined by the presence of respiratory distress, as indicated by an increased oxygen requirement ($FiO_2 \geq 0.4$) and compatible chest ra-

Table 1. Definition for histologic chorioamnionitis

Items	Definitions
Grading system for histologic chorioamnionitis, quoted from Salafia et al. (13)	
Amnion and chorion-decidua	
Grade 1	One focus of at least five PMN
Grade 2	More than one focus of grade 1 inflammation, or at least one focus of five to 20 PMN
Grade 3	Multiple and/or confluent foci of grade 2
Grade 4	Diffuse and dense acute inflammation
Umbilical cord	
Grade 1	PMN within the inner third of the umbilical vein wall
Grade 2	PMN within the inner third of at least two umbilical vessel walls
Grade 3	PMN in the perivascular Wharton jelly
Grade 4	Panvasculitis and funisitis extending deep into the Wharton jelly
Chorionic plate	
Grade 1	One focus of at least five PMN in subchorionic fibrin
Grade 2	Multiple foci of grade 1 in subchorionic fibrin
Grade 3	Few PMN in connective tissue or chorionic plate
Grade 4	Numerous PMN in chorionic plate, and chorionic vasculitis
Modified definition for histologic chorioamnionitis based on the site and extent of inflammation	
Any HC	PMN infiltration of any grade in any part of the amnion, chorionic decidua, umbilical cord or chorionic plate
Amnionitis	PMN infiltration of any grade in the amnion
<i>High grade amnionitis</i>	<i>PMN infiltration of grade 3 or more in the amnion</i>
Funisitis	PMN infiltration of any grade in the umbilical cord
<i>High grade funisitis</i>	<i>PMN infiltration of grade 3 or more in the umbilical cord</i>
Amnionitis + funisitis	PMN infiltration of any grade in the part of the amnion and umbilical cord
<i>High grade amnionitis + funisitis</i>	<i>PMN infiltration of grade 3 or more in the amnion and umbilical cord</i>

HC, histologic chorioamnionitis; PMN, polymorphonuclear leukocytes.

diographic findings without any evidence of another cause of respiratory distress; bronchopulmonary dysplasia (BPD), defined as supplemental oxygen dependency at 36th week post-menstrual age; early-onset sepsis (EOS) and late-onset sepsis (LOS), defined as a systemic bacterial infection documented by a positive blood culture within the first 72 hr of life or after the first 72 hr of life, respectively, with a clinical presentation consistent with sepsis; intraventricular hemorrhage (IVH) and periventricular leukomalacia (PVL), diagnosed via cranial ultrasonography; necrotizing enterocolitis (NEC), defined according to Bell's criteria (14); and retinopathy of prematurity (ROP), defined based on the International Classification of ROP.

Statistical analysis

Statistical analyses were performed using the SPSS software, Version 21.0 (SPSS, Inc., Chicago, IL, USA). Continuous variables were expressed as means and standard deviations or as medians and interquartile ranges, and were analyzed using either Student's *t*-test or the Mann-Whitney U-test. Categorical variables were expressed as proportions (%), and chi-square or Fisher's exact tests (two-sided) were used for comparisons. Logistic regression analysis was performed to adjust for both GA and birth weight. Adjusted odds ratios (aOR) and 95% confidence intervals (CI) were reported, and a *P* value < 0.05 was considered statistically significant.

Ethics statement

This study was approved by the institutional review board (IRB) of Seoul National University Bundang Hospital (IRB No. B1410-271-107). Informed consent was waived by the board due to a retrospective nature of this study.

RESULTS

Subjects enrolled

During the study period, 261 VLBW infants were born and admitted at our neonatal intensive care unit, and their eligibility to participate in the study was assessed. Among them, two infants with insufficient placental histologic data and one infant with congenital anomaly were excluded.

Histologic chorioamnionitis based on the site of inflammation

Of the remaining 258 infants, 99 (38.4%) infants were exposed to any HC. The demographic and perinatal characteristics of the VLBW infants who were exposed and not exposed to HC based on the site of inflammation are shown in Table 2. Mothers with HC were more likely to have PROM and clinical chorioamnionitis, receive antibiotics, and deliver vaginally. Mothers without HC were more likely to have preeclampsia. The mean GA was significantly lower in the HC-exposed infants in all sites of inflammation. The HC-exposed infants were more likely to be of singleton and less likely to be SGA. There were no significant differences in the maternal age, antenatal steroid exposure rate, birth weight, sex, and Apgar scores at 1 and 5 min between the HC-exposed and unexposed infants in all sites of inflammation. The mortality and neonatal morbidities between the HC-exposed and unexposed VLBW infants were shown in Table 3. Twenty five (9.7%) infants out of a total of 258 died within 28 days of birth, and there were no differences in the mortality rates between the HC-exposed and unexposed infants in all sites of inflammation. The incidences of RDS, NEC, IVH of \geq grade 3, PVL, EOS and LOS were not different between HC-exposed and unexposed infants in all sites of inflammation either. However,

Table 2. Demographic and perinatal characteristics of very low birth weight infants with histologic chorioamnionitis defined based on the site of inflammation

Parameters	Any HC		Amnionitis		Funisitis		Amnionitis + funisitis	
	+	-	+	-	+	-	+	-
	(n = 99)	(n = 159)	(n = 19)	(n = 239)	(n = 34)	(n = 224)	(n = 13)	(n = 245)
Maternal age [†] (yr)	32.4 ± 3.8	32.8 ± 3.9	33.8 ± 3.7	32.5 ± 3.8	32.8 ± 3.4	32.6 ± 3.9	32.8 ± 3.2	32.6 ± 3.9
Cesarean section (%)	57.6*	88.1	26.3*	80.3	41.2*	81.7	15.4*	79.6
Antenatal steroid (%)	85.9	78.0	89.5	80.3	91.2	79.5	84.6	80.8
ROM > 18 hr (%)	62.6*	17.0	100*	29.3	88.2*	26.3	100*	31.0
Intrapartum antibiotic exposure (%)	54.5*	13.8	78.9*	25.5	73.5*	22.8	69.2*	27.3
Clinical chorioamnionitis (%)	8.1*	0	5.3	2.9	14.7*	1.3	7.7	2.9
Maternal PE (%)	11.1*	44.7	0*	34.3	2.9*	36.2	0*	33.5
Gestational age [†] (weeks)	28 ⁺¹ ± 2 ^{+5*}	29 ⁺⁶ ± 2 ⁺⁶	27 ⁺⁴ ± 2 ^{+1*}	29 ⁺³ ± 2 ⁺⁶	27 ⁺⁵ ± 2 ^{+3*}	29 ⁺³ ± 2 ⁺⁶	27 ⁺⁶ ± 2 ^{+1*}	29 ⁺² ± 2 ⁺⁶
Birth weight [†] (g)	1,089 ± 261	1,113 ± 275	1,078 ± 279	1,073 ± 291	1,051 ± 291	1,076 ± 290	1,094 ± 288	1,072 ± 290
Male (%)	57.6*	44.7	47.4	49.8	47.1	50.0	46.2	49.8
Multiple births (%)	22.2*	35.2	0*	32.6	8.8*	33.5	0*	31.8
SGA (%)	18.2*	49.7	15.8*	39.3	14.7*	41.1	15.4	38.8
Apgar score at 1 min [†]	5 (3-6)	4 (3-6)	6 (3-6)	5 (3-6)	5 (2-6)	5 (3-6)	6 (5-6.5)	5 (3-6)
Apgar score at 5 min [†]	7 (6-7.25)	7 (6-8)	7 (6-8)	7 (6-8)	7 (5-7)	7 (6-8)	7 (6-7.5)	7 (6-8)

**P* < 0.05; [†]Data expressed as the means ± standard deviations; [‡]Data expressed as medians (interquartile ranges). HC, histologic chorioamnionitis; ROM, rupture of membrane; PE, preeclampsia; SGA, small for gestational age.

the incidence of BPD was higher in amnionitis-exposed infants (50% vs. 23.6%, $P = 0.02$). Severe ROP (\geq stage 3) and the need for laser surgery were significantly associated with any HC and funisitis (Table 3).

Histologic chorioamnionitis based on the extent of inflammation

Although further analysis on the sub-definitions of HG HC was carried out to observe whether the extent of inflammation in each site further affects the morbidity and mortality of the VLBW infants, there was no significant finding except that BPD

occurred more often in infants who were exposed to HG amnionitis than who were not (66.7% vs. 24.0%, $P = 0.01$) (Table 4).

Independent association with neonatal morbidities

We performed further analysis to adjust for both GA and birth weight using logistic regression model (Table 5). After adjustment, the RDS was significantly fewer in HC-exposed infants than in HC-unexposed infants except for the infants who were exposed to HG amnionitis and HG funisitis. Although analysis included HG amnionitis plus funisitis, there was only one case of HG amnionitis plus funisitis, therefore statistical analysis was

Table 3. Mortality and neonatal morbidities of very low birth weight infants with histologic chorioamnionitis defined based on the site of inflammation

Parameters	Any HC		Amnionitis		Funisitis		Amnionitis + funisitis	
	+	-	+	-	+	-	+	-
	(n = 99)	(n = 159)	(n = 19)	(n = 239)	(n = 34)	(n = 224)	(n = 13)	(n = 245)
Mortality (%)	8 (8.1)	17 (10.7)	1 (5.3)	24 (10.0)	3 (8.8)	22 (9.8)	1 (7.7)	24 (9.8)
RDS (%)	57/99 (57.6)	90/159 (61.2)	8/19 (42.1)	139/239 (58.2)	17/34 (50.0)	130/224 (58.0)	5/13 (38.5)	142/245 (58.0)
BPD (%)	28/92 (30.4)	32/142 (22.5)	9/18 (50.0)*	51/216 (23.6)	9/31 (29.0)	51/203 (25.1)	4/12 (33.3)	56/222 (25.2)
NEC (%)	6/93 (6.5)	10/145 (6.9)	1/18 (5.6)	15/220 (6.8)	3/31 (9.7)	13/207 (6.3)	1/12 (8.3)	15/226 (6.6)
IVH \geq Gr 3 (%)	7/92 (7.6)	6/143 (4.2)	0/18 (0)	13/217 (6.0)	3/31 (9.7)	10/204 (4.9)	0/12 (0)	13/223 (5.8)
PVL (%)	5/92 (5.4)	12/143 (8.4)	0/18 (0)	17/217 (7.8)	3/31 (9.7)	14/204 (6.9)	0/12 (0)	17/223 (7.6)
EOS (%)	1/94 (1.1)	2/148 (1.4)	0/18 (0)	3/224 (1.3)	0/32 (0)	3/210 (1.4)	0/12 (0)	3/230 (1.3)
LOS (%)	8/92 (8.7)	14/144 (9.7)	3/18 (16.7)	19/218 (8.7)	1/31 (3.2)	21/205 (10.2)	1/12 (8.3)	21/224 (9.4)
Severe ROP (%)	26/92 (28.3)*	24/143 (16.8)	6/18 (33.3)	44/217 (20.3)	11/31 (35.5)*	39/204 (19.1)	3/12 (25.0)	47/223 (21.1)
Laser surgery (%)	23/92 (25.0)*	16/142 (11.3)	5/18 (27.8)	34/216 (15.7)	9/31 (29.0)*	30/203 (14.8)	3/12 (25.0)	36/222 (16.2)

* $P < 0.05$. HC, histologic chorioamnionitis; BPD, bronchopulmonary dysplasia; EOS, early onset sepsis; IVH, intraventricular hemorrhage; LOS, late onset sepsis; NEC, necrotizing enterocolitis; PVL, periventricular leukomalacia; RDS, respiratory distress syndrome; ROP, retinopathy of prematurity.

Table 4. Mortality and neonatal morbidities of very low birth weight infants with high grade histologic chorioamnionitis defined based on the extent of inflammation

Parameters	High grade amnionitis		High grade funisitis		High grade amnionitis + funisitis	
	+	-	+	-	+	-
	(n = 10)	(n = 248)	(n = 20)	(n = 238)	(n = 2)	(n = 256)
Mortality (%)	1 (10.0)	24 (9.7)	1 (5.0)	24 (10.1)	1 (50.0)	24 (9.4)
RDS (%)	5/10 (50.0)	142/248 (57.3)	11/20 (55.0)	136/238 (57.1)	2/2 (100.0)	145/256 (56.6)
BPD (%)	6/9 (66.7)*	54/225 (24.0)	5/19 (26.3)	55/215 (25.6)	1/1 (100.0)	59/233 (25.3)
NEC (%)	1/9 (11.1)	15/229 (6.6)	1/19 (5.3)	15/219 (6.8)	0/1 (0)	16/237 (6.8)
IVH \geq Gr 3 (%)	0/9 (0)	13/226 (5.8)	2/19 (10.5)	11/216 (5.1)	0/1 (0)	13/234 (5.6)
PVL (%)	0/9 (0)	17/226 (7.5)	2/19 (10.5)	15/216 (6.9)	0/1 (0)	17/234 (7.3)
EOS (%)	0/9 (0)	3/233 (1.3)	0/19 (0)	3/223 (1.3)	0/1 (0)	3/241 (1.2)
LOS (%)	2/9 (22.2)	20/227 (8.8)	0/19 (0)	22/217 (10.1)	0/1 (0)	22/235 (9.4)
Severe ROP (%)	3/9 (33.3)	47/226 (20.8)	7/19 (36.8)	43/216 (19.9)	0/1 (0)	50/234 (21.4)
Laser surgery (%)	3/9 (33.3)	36/225 (16.0)	5/19 (26.3)	34/215 (15.8)	0/1 (0)	39/233 (16.7)

* $P < 0.05$. BPD, bronchopulmonary dysplasia; EOS, early onset sepsis; Gr, grade; IVH, intraventricular hemorrhage; LOS, late onset sepsis; NEC, necrotizing enterocolitis; PVL, periventricular leukomalacia; RDS, respiratory distress syndrome; ROP, retinopathy of prematurity.

Table 5. The relationship between neonatal morbidities and histologic chorioamnionitis defined based on the site and extent of inflammation

Complications	Any HC aOR (95% CI)	Amnionitis aOR (95% CI)	High grade amnionitis aOR (95% CI)	Funisitis aOR (95% CI)	High grade funisitis aOR (95% CI)	Amnionitis + funisitis aOR (95% CI)
RDS	0.36 (0.17-0.74)*	0.16 (0.04-0.61)*	0.20 (0.04-1.20)	0.24 (0.09-0.65)*	0.34 (0.10-1.17)	0.15 (0.03-0.75)*
BPD	0.85 (0.40-1.80)	2.73 (0.79-9.47)	7.37 (1.18-46.12)*	0.67 (0.24-1.84)	0.49 (0.14-1.68)	1.10 (0.24-4.76)
Severe ROP	1.19 (0.49-2.88)	1.22 (0.26-5.66)	0.77 (0.10-5.90)	1.61 (0.49-5.26)	1.2 (0.3-4.88)	0.77 (0.12-5.03)
Laser surgery	1.54 (0.59-4.01)	1.03 (0.21-5.04)	1.21 (0.16-9.46)	1.28 (0.37-4.40)	0.65 (0.15-2.88)	1.18 (0.18-7.74)

Adjusted for gestational age and birth weight using logistic regression model. * $P < 0.05$. aOR, adjusted odds ratio; HC, histologic chorioamnionitis; BPD, bronchopulmonary dysplasia; CI, confidence intervals; RDS, respiratory distress syndrome; ROP, retinopathy of prematurity.

irrelevant. The incidence of BPD was higher only in infants who were exposed to HG amnionitis than who were not (aOR, 7.37; 95% CI, 1.18-46.12). The relationship of HC with severe ROP and the need for laser surgery disappeared after adjustment for GA and birth weight (Table 5).

DISCUSSION

The primary findings in the present study include a significant association of HC with a reduced incidence of RDS and HG amnionitis with an increased incidence of BPD. Other neonatal morbidities were not associated with HC following adjustment for GA and birth weight. Because the GA was significantly lower in the VLBW infants exposed to HC, adjustment for GA as well as birth weight was needed.

Many studies have supported the idea that HC protects against RDS. Watterberg et al. (15) observed that the increased production of inflammatory cytokines and cortisol accelerate lung maturation and that this process decreases the incidence of RDS. Since the beginning of the era of antenatal steroid treatment, several studies have reexamined the effects of HC. Lahra et al. (16) demonstrated that HC was associated with a significant reduction of RDS; chorioamnionitis with umbilical vasculitis is particularly associated with a markedly reduced incidence of RDS compared with chorioamnionitis alone. Other studies have also described a reduction of RDS among the HC-exposed preterm infants (3, 4). In those studies, the antenatal steroid exposure rate was not different between the HC-exposed and unexposed infants. In the present study, antenatal steroid exposure rate was not different between the HC-exposed and unexposed infants in all site of inflammation either. When adjusted for GA and birth weight, any HC, amnionitis, funisitis, and amnionitis plus funisitis were all significantly associated with a decreased incidence of RDS. These findings support the idea that HC still has a beneficial effect that protects RDS in the era of antenatal steroid treatment. It deserves special mention that HG amnionitis and HG funisitis were not associated with a reduced incidence of RDS. In our previous retrospective cohort study, more severe HC led to RDS and alter the response to surfactant (17). High grade chorioamnionitis may cause a pneumonia in the fetus and newborn preterm infants which is not distinguished clinically from RDS (18). The absence of significant association of HG amnionitis and HG funisitis with the reduced incidence of RDS supports the idea that more severe chorioamnionitis may offset the beneficial effect of HC.

The relationship between chorioamnionitis and BPD is still controversial. The most recent evidence suggests that a maturational effect exerted by HC appears to decrease the incidence of RDS in preterm infants but also contribute to the increased susceptibility to postnatal lung injury (5, 15, 19, 20). One study demonstrated that exposure to both HC with/without funisitis

and prolonged mechanical ventilation increased the risk of BPD (21) while another study suggested funisitis is protective for BPD (22). A recent systematic review by Hartling et al. (9) showed that HC is significantly associated with the increased incidence of BPD. However, the definition of HC was not consistent across all studies and the authors found a strong evidence of publication bias, which makes the association of HC with BPD inauthentic. In the present study, BPD was not associated with HC of any sites except for HG amnionitis. High grade amnionitis was significantly associated with BPD even after adjustment for GA and birth weight while HG funisitis was not. The reason for this result is unclear but may be related to the observation that severe amnionitis is strongly associated with an intense intra-amniotic inflammatory process (12). Considering the location of the amnion that lines the amniotic cavity, HG amnionitis may portray the presence of a strong chemotactic stimuli present within the amniotic cavity. Several studies unveiled an association between elevated concentrations of pro-inflammatory cytokines in the amniotic fluid and the development of BPD (23-26). Although the underlying inflammatory mechanisms of HC are not fully understood, pro-inflammatory cytokines aspirated by the fetus can directly contact with respiratory epithelium and induce pulmonary inflammation. Fetal pulmonary inflammation can inactivate surfactant and make the lung more susceptible for further injury from oxygen toxicity or mechanical ventilation eventually leading to BPD. The finding that HG amnionitis but not HG funisitis was associated with BPD suggests that fetal pulmonary inflammation via direct contact with the airway epithelium might be more responsible for the development of BPD than fetal systemic inflammation via umbilical cord.

A number of studies have attempted to evaluate the relationship between HC and ROP. Dammann et al. (27) found evidence supporting the idea that extreme prematurity and multiple hits of perinatal inflammation may contribute to an increased risk of ROP. In contrast, Woo et al. (28) reported that neither HC nor funisitis were associated with ROP. A recent systematic review reported that chorioamnionitis was significantly associated with severe ROP. However, the relationship disappeared after adjustment for GA; the authors concluded that chorioamnionitis cannot be considered a definitive risk factor for ROP (29). Our study also found that the relationship of HC with severe ROP and an increased incidence of laser surgery disappeared following adjustment for GA and birth weight.

The limitations of this study include that this is a single center study and is of retrospective nature. The strengths of this study include: the histological diagnosis of chorioamnionitis was made via a consistent standardized placental assessment by a single pathologist; the definition of HC reflected both the site and extent of inflammation; the study was performed in the era of prenatal steroid treatment.

In conclusion, the results of the present study show that HC

significantly decreased the incidence of RDS and HG amnionitis increased the incidence of BPD in VLBW infants while lacking association with other neonatal morbidities. These results suggest that the association with HC and neonatal morbidities may differ by the site and extent of chorioamnionitis. We suggest that it is not simply the presence or absence of HC but both the location and severity of HC that correlates with adverse neonatal outcomes. Further studies designed to evaluate the interactions of HC with various postnatal factors are necessary.

DISCLOSURE

The authors have nothing to disclose as to conflicts of interest.

AUTHOR CONTRIBUTION

Conception and coordination of the study: Choi CW. Design of ethical issues: Kim SY, Choi CW, Kim BI. Acquisition of data: Kim SY, Jung E, Kim H. Data review: Kim SY, Jung E, Choi CW, Kim BI. Statistical analysis: Kim SY, Choi CW. Manuscript preparation: Kim SY, Choi CW, Lee J, Lee JA, Kim EK, Kim HS, Kim BI, Choi JH. Manuscript approval: all authors.

ORCID

Su Yeong Kim <http://orcid.org/0000-0001-6463-0210>
 Chang Won Choi <http://orcid.org/0000-0003-1911-0253>
 Euseok Jung <http://orcid.org/0000-0003-0693-5627>
 Juyoung Lee <http://orcid.org/0000-0001-7548-2284>
 Jin A Lee <http://orcid.org/0000-0002-9194-0529>
 Haeryoung Kim <http://orcid.org/0000-0002-4205-9081>
 Ee-Kyung Kim <http://orcid.org/0000-0002-7063-168X>
 Han-Suk Kim <http://orcid.org/0000-0002-9777-3231>

REFERENCES

1. Yoon BH, Romero R, Park JS, Kim M, Oh SY, Kim CJ, Jun JK. *The relationship among inflammatory lesions of the umbilical cord (funisitis), umbilical cord plasma interleukin 6 concentration, amniotic fluid infection, and neonatal sepsis.* *Am J Obstet Gynecol* 2000; 183: 1124-9.
2. Ramsey PS, Lieman JM, Brumfield CG, Carlo W. *Chorioamnionitis increases neonatal morbidity in pregnancies complicated by preterm premature rupture of membranes.* *Am J Obstet Gynecol* 2005; 192: 1162-6.
3. Dempsey E, Chen MF, Kokottis T, Vallerand D, Usher R. *Outcome of neonates less than 30 weeks gestation with histologic chorioamnionitis.* *Am J Perinatol* 2005; 22: 155-9.
4. Andrews WW, Goldenberg RL, Faye-Petersen O, Cliver S, Goepfert AR, Hauth JC. *The Alabama Preterm Birth study: polymorphonuclear and mononuclear cell placental infiltrations, other markers of inflammation, and outcomes in 23- to 32-week preterm newborn infants.* *Am J Obstet Gynecol* 2006; 195: 803-8.
5. Speer CP. *Neonatal respiratory distress syndrome: an inflammatory disease?* *Neonatology* 2011; 99: 316-9.
6. Erdemir G, Kultursay N, Calkavur S, Zekioglu O, Koroglu OA, Cakmak B, Yalaz M, Akisu M, Sagol S. *Histological chorioamnionitis: effects on premature delivery and neonatal prognosis.* *Pediatr Neonatol* 2013; 54: 267-74.
7. Soraisham AS, Trevenen C, Wood S, Singhal N, Sauve R. *Histological chorioamnionitis and neurodevelopmental outcome in preterm infants.* *J Perinatol* 2013; 33: 70-5.
8. Lee HJ, Kim EK, Kim HS, Choi CW, Kim BI, Choi JH. *Chorioamnionitis, respiratory distress syndrome and bronchopulmonary dysplasia in extremely low birth weight infants.* *J Perinatol* 2011; 31: 166-70.
9. Hartling L, Liang Y, Lacaze-Masmonteil T. *Chorioamnionitis as a risk factor for bronchopulmonary dysplasia: a systematic review and meta-analysis.* *Arch Dis Child Fetal Neonatal Ed* 2012; 97: F8-17.
10. Reilly SD, Faye-Petersen OM. *Chorioamnionitis and Funisitis Their Implications for the Neonate.* *Neoreviews* 2008; 9: e411-7.
11. Jessop F, Sebire N. *Histologic chorioamnionitis: current concepts of diagnosis classification and clinical significance.* *Fetal Matern Med Rev* 2011; 22: 25-44.
12. Park CW, Moon KC, Park JS, Jun JK, Romero R, Yoon BH. *The involvement of human amnion in histologic chorioamnionitis is an indicator that a fetal and an intra-amniotic inflammatory response is more likely and severe: clinical implications.* *Placenta* 2009; 30: 56-61.
13. Salafia CM, Weigl C, Silberman L. *The prevalence and distribution of acute placental inflammation in uncomplicated term pregnancies.* *Obstet Gynecol* 1989; 73: 383-9.
14. Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, Brotherton T. *Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging.* *Ann Surg* 1978; 187: 1-7.
15. Watterberg KL, Demers LM, Scott SM, Murphy S. *Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops.* *Pediatrics* 1996; 97: 210-5.
16. Lahra MM, Beeby PJ, Jeffery HE. *Maternal versus fetal inflammation and respiratory distress syndrome: a 10-year hospital cohort study.* *Arch Dis Child Fetal Neonatal Ed* 2009; 94: F13-6.
17. Choi CW, Kim BI, Koh YY, Choi JH, Choi JY. *Clinical characteristics of chronic lung disease without preceding respiratory distress syndrome in preterm infants.* *Pediatr Int* 2005; 47: 72-9.
18. Kallapur SG, Kramer BW, Jobe AH. *Ureaplasma and BPD.* *Semin Perinatol* 2013; 37: 94-101.
19. Been JV, Rours IG, Kornelisse RF, Jonkers F, de Krijger RR, Zimmermann LJ. *Chorioamnionitis alters the response to surfactant in preterm infants.* *J Pediatr* 2010; 156: 10-5.e1.
20. Plakkal N, Soraisham AS, Trevenen C, Freiheit EA, Sauve R. *Histological chorioamnionitis and bronchopulmonary dysplasia: a retrospective cohort study.* *J Perinatol* 2013; 33: 441-5.
21. Van Marter LJ, Dammann O, Allred EN, Leviton A, Pagano M, Moore M, Martin C; Developmental Epidemiology Network Investigators. *Chorioamnionitis, mechanical ventilation, and postnatal sepsis as modulators of chronic lung disease in preterm infants.* *J Pediatr* 2002; 140: 171-6.
22. Lahra MM, Beeby PJ, Jeffery HE. *Intrauterine inflammation, neonatal sepsis, and chronic lung disease: a 13-year hospital cohort study.* *Pediatrics* 2009; 123: 1314-9.
23. Groneck P, Götze-Speer B, Oppermann M, Eiffert H, Speer CP. *Association of pulmonary inflammation and increased microvascular permeability.*

- bility during the development of bronchopulmonary dysplasia: a sequential analysis of inflammatory mediators in respiratory fluids of high-risk preterm neonates. *Pediatrics* 1994; 93: 712-8.
24. Yoon BH, Romero R, Jun JK, Park KH, Park JD, Ghezzi F, Kim BI. Amniotic fluid cytokines (interleukin-6, tumor necrosis factor- α , interleukin- β , and interleukin-8) and the risk for the development of bronchopulmonary dysplasia. *Am J Obstet Gynecol* 1997; 177: 825-30.
25. Ghezzi F, Gomez R, Romero R, Yoon BH, Edwin SS, David C, Janisse J, Mazor M. Elevated interleukin-8 concentrations in amniotic fluid of mothers whose neonates subsequently develop bronchopulmonary dysplasia. *Eur J Obstet Gynecol Reprod Biol* 1998; 78: 5-10.
26. Choi CW, Kim BI, Joung KE, Lee JA, Lee YK, Kim EK, Kim HS, Park JD, Choi JH. Decreased expression of transforming growth factor-beta1 in bronchoalveolar lavage cells of preterm infants with maternal chorioamnionitis. *J Korean Med Sci* 2008; 23: 609-15.
27. Dammann O, Brinkhaus MJ, Bartels DB, Dördelmann M, Dressler F, Kerk J, Dörk T, Dammann CE. Immaturity, perinatal inflammation, and retinopathy of prematurity: a multi-hit hypothesis. *Early Hum Dev* 2009; 85: 325-9.
28. Woo SJ, Park KH, Jung HJ, Kim S, Choe G, Ahn J, Park KH. Effects of maternal and placental inflammation on retinopathy of prematurity. *Graefes Arch Clin Exp Ophthalmol* 2012; 250: 915-23.
29. Mitra S, Aune D, Speer CP, Saugstad OD. Chorioamnionitis as a risk factor for retinopathy of prematurity: a systematic review and meta-analysis. *Neonatology* 2014; 105: 189-99.